Involvement of endothelin-1 and its receptors in PGF2alpha-induced luteolysis in the rat.
The possible mediatory role of endothelin-1 (ET-1) in prostaglandin F(2alpha) (PGF(2alpha))-induced luteolysis in the rat was examined. The effect of PGF(2alpha) was tested on day 9 of pregnancy either in vivo, by injecting cloprostenol, an analog of PGF(2alpha) or in vitro, in isolated intact corpora lutea incubated with PGF(2alpha). Luteolysis was confirmed by progesterone determination in the peripheral blood serum or in the culture medium, respectively. Administration of cloprostenol (.0025 mg/rat) induced within 1 hr, a significant fall (from 56.8 to 27.6 ng/ml, P < 0.0001) in serum progesterone concentrations that was associated with an increased expression of the mRNA to ET-1 and its protein product in rat luteal tissue. Elevated level of ET-1 were also determined at the spontaneous regression of the CL, upon parturition. Expression of the ET receptors, ETA and ETB was not affected by cloprostenol. On the other hand, this PGF(2alpha) analog induced expression of luteal VEGF mRNA. In vitro experiments demonstrate that the LH (100 ng/ml)-induced increase in luteal progesterone secretion was reduced by PGF(2alpha) (1 microg/ml). The inhibitory effect of PGF(2alpha) was reversed by BQ123 (10(- 7) M), that is a selective ETA receptor antagonist. We conclude that the PGF(2alpha)-induced elevation in luteal expression of ET-1 combined with the reversal of its luteolytic effect by an ETA receptor antagonist suggest that ET-1 may take part in the PGF(2alpha)-induced luteolysis in the rat.
Girsh
Eliezer
E
Department of Biological Regulation, Weizmann Institute, Rehovot, Israel.
Dekel
Nava
N
D000818:Animals; D015153:Blotting, Western; D015687:Cell Hypoxia; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D015237:Dinoprost / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000096:biosynthesis / Q000235:genetics; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D036341:Intercellular Signaling Peptides and Proteins / Q000096:biosynthesis / Q000235:genetics; D003341:Luteolysis / Q000187:drug effects / Q000502:physiology*; D008222:Lymphokines / Q000096:biosynthesis / Q000235:genetics; D010456:Peptides, Cyclic / Q000494:pharmacology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D014661:Vasoconstriction / Q000187:drug effects
D016228:Endothelial Growth Factors; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010456:Peptides, Cyclic; D012333:RNA, Messenger; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B; D017466:Receptors, Endothelin; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003008:Cloprostenol; D011374:Progesterone; D015237:Dinoprost; C072247:cyclo(Trp-Asp-Pro-Val-Leu)